Floatz logo

Tuvusertib

Recurrent Endometrial Endometrioid Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Recurrent Endometrial Endometrioid Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Arimidex
Memorial Sloan Kettering Cancer Center
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Tazemetostat
National Cancer Institute (NCI)
Phase 2CCC
Tirzepatide
UNC Lineberger Comprehensive Cancer Center
Phase 2CCC

View all 14 →

Same molecule, other indications

Tuvusertib is also rated in:

prostate carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
53 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →